CELH
Celsius Holdings, Inc.
CELH has the edge over CL overall, supported by stronger fundamentals and stronger modeled upside.
CL
Colgate-Palmolive Company
CL has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
CL's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over CL in the historical PE scenario, which offers more potential upside but is not a forecast.
CL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $63.39 | -35% |
| Forward | 25x | $97.90 | — |
| Fair | 28x | $72.66 | -26% |
| Expensive | 35x | $90.47 | -7.6% |
| Current | 38x | $97.90 | — |
Historical ranges are pointers, not guarantees.
CL's PE is in its expensive range at 38x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its cheap range.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over CL on the outlook, with more favorable revenue expectations.
CL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect CL's earnings to grow and its profitability to improve, with its revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
CL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.00 | +56% |
| Q3 2026 | $2.56 | -28% |
| Q2 2026 | $2.53 | -29% |
| Q1 2026 | $2.58 | -27% |
| Q4 2025 | $2.63 | -25% |
| Q3 2025 | $3.56 | +2.3% |
| Q2 2025 | $3.55 | +3.2% |
| Q1 2025 | $3.53 | +12% |
| Q4 2024 | $3.51 | +27% |
CL has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over CL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH's operating margin was 20% last quarter, up 31 points from the same quarter a year ago.
CL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.4B | +4.6% |
| Q2 2026 | $5.4B | +4.9% |
| Q1 2026 | $5.3B | +8.4% |
| Q4 2025 | $5.2B | +5.8% |
| Q3 2025 | $5.1B | +1.9% |
| Q2 2025 | $5.1B | +1% |
| Q1 2025 | $4.9B | -3% |
| Q4 2024 | $4.9B | -0.1% |
CL's revenue has grown year over year for six quarters in a row: $5.4B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -0.4 points |
| Q2 2026 | 19% | -2.2 points |
| Q1 2026 | 18% | -3.8 points |
| Q4 2025 | 1.8% | -20 points |
| Q3 2025 | 21% | -0.5 points |
| Q2 2025 | 21% | -0.4 points |
| Q1 2025 | 22% | +1.2 points |
| Q4 2024 | 22% | -0.2 points |
CL's operating margin was 20% last quarter, about level with the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
CL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1B | -6.2% |
| Q2 2026 | $867M | +12% |
| Q1 2026 | $609M | +28% |
| Q4 2025 | $1.3B | +18% |
| Q3 2025 | $1.1B | +7.1% |
| Q2 2025 | $776M | -11% |
| Q1 2025 | $476M | -14% |
| Q4 2024 | $1.1B | +16% |
CL has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
CL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -2.1M shares |
| 1 year | -1.3% | -10.5M shares |
| 3 years | -3.3% | -27.6M shares |
| 5 years | -5.5% | -46.7M shares |
| Available history | -7.1% | -61.4M shares |
CL has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $330M |
| Q2 2026 | $291M |
| Q1 2026 | $306M |
| Q4 2025 | $406M |
| Q3 2025 | $288M |
| Q2 2025 | $232M |
| Q1 2025 | $284M |
| Q4 2024 | $455M |
CL spent $1.3B buying back its own shares over the past year, up 5.9% from the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over CL on leverage, with a lower net debt burden relative to earnings.
CL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | 1.4x | Healthy |
CL's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
CL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.1 | Neutral |
| Stochastic | 77.5 | Neutral |
CL's weekly RSI is 65 (neutral) and its Stochastic is 78 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH has the edge over CL on valuation relative to its sector.
CL PE vs Consumer Defensive Sector
| Metric | CL | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 19x | 96% above |
| PE % | 90 | 18 | 72 pts above |
CL is trading at 38x earnings, a 96% premium to the Consumer Defensive sector's median of 19x.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
CL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $92.1 | 6.3% above |
| 20 week MA | $91.5 | 7.1% above |
| 50 week MA | $88.9 | 10% above |
| 100 week MA | $88.0 | 11% above |
| 200 week MA | $86.3 | 13% above |
CL has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
CL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.2 | $85.0 | +23% |
| 2021 | $85.0 | $82.8 | -2.6% |
| 2022 | $82.8 | $79.5 | -4% |
| 2023 | $79.5 | $79.7 | +0.3% |
| 2024 | $79.7 | $91.8 | +15% |
| 2025 | $91.8 | $79.7 | -13% |
| 2026 YTD | $79.7 | $97.9 | +23% |
CL has the edge over CELH on returns for 2026, with the stronger performance.